哌醋甲酯
内科学
注意缺陷多动障碍
医学
内分泌学
催乳素
三碘甲状腺素
激素
甲状腺
甲状腺功能
阿托莫西汀
促甲状腺激素
儿科
精神科
作者
Liang‐Jen Wang,Ying-Hua Huang,Wen‐Jiun Chou,Sheng-Yu Lee
标识
DOI:10.1210/clinem/dgac139
摘要
Abstract Context The trends in hormone indices of children with attention deficit hyperactivity disorder (ADHD) who received long-term medication treatment remains controversial. Objective This prospective study aimed to examine the changes in the growth hormone and thyroid hormone systems among children with ADHD undergoing various medication treatments. Methods In total, 118 children who were diagnosed with ADHD and were drug-naive were observed naturalistically over 12 months. Of them, 22 did not receive any medication, while 39, 40, and 17 were treated with low doses of short-acting methylphenidate (MPH) (14 ± 6.7 mg/day), osmotic-release oral system (OROS) long-acting MPH (32 ± 9.6 mg/day), and atomoxetine (29.2 ± 9.7 mg/day), respectively. Blood samples were obtained at both the baseline and the endpoint (month 12) to measure serum levels of insulin-like growth factor 1 (IGF-1), IGF binding protein 3 (IGFBP-3), prolactin, thyroid-stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), and free T4. Results Trends for IGF-1, IGFBP-3, prolactin, TSH, T3, T4, and free T4 levels were similar among the 4 groups. Changes in serum levels of IGF-1 were positively correlated with changes in height and weight of all the children with ADHD. However, patients who received MPH treatment had less body weight gain than the nonmedicated group. The ratio of MPH doses to body weight was inversely correlated with the increment in height. Conclusion There were no changes in thyroid or growth hormones associated with the low doses of ADHD medications used in this study within 1 year’s duration. Nonetheless, patients’ growth and the appropriateness of drug dosage should be closely monitored.
科研通智能强力驱动
Strongly Powered by AbleSci AI